Can I read O03: A randomized controlled trial to compare the efficacy and safety of apremilast and methotrexate in patients with palmoplantar psoriasis on EtoBox?

O03: A randomized controlled trial to compare the efficacy and safety of apremilast and methotrexate in patients with palmoplantar psoriasis is a Medicine article available to read on EtoBox.

What is O03: A randomized controlled trial to compare the efficacy and safety of apremilast and methotrexate in patients with palmoplantar psoriasis about?

The aim of this study was to evaluate the use of doxycycline and implementation of the BLISTER trial in a cohort of patients with BP using real-world data from a dermatology specialist centre. Sixty-four adult patients with a diagnosis of BP between January 2014 and December 2017 were included in this study. Patients were followed-up for a mean of 469 days. Doxycycline was used in 92% of those given systemic treatment and was started as initial treatment in 44 cases (69%). Of these, 21 (48%) had doxycycline without prednisolone and 23 (52%) had doxycycline combined with prednisolone. Of the former group, 18 were followed for at least 6 weeks. Of these, 13 (72%) required additional oral prednisolone. Only eight patients (12%) had doxycycline as the only systemic agent prescribed throughout. Fifty-seven patients were given prednisolone at some point. Over time, the dose of prednisolone had to be increased (compared to the starting dose) in 12 patients in order to achieve control. Ten of these patients were on doxycycline. During follow-up, 56 relapses were recorded, 29 (52%) of which were in patients on doxycycline. Thirty-two (57%) of the relapses coincided with the tailing off of p

Who reads O03: A randomized controlled trial to compare the efficacy and safety of apremilast and methotrexate in patients with palmoplantar psoriasis?

Publisher

Oxford University Press (OUP)

Published

2021

Language

EN

Field

Medicine (Health Sciences)